功能性膜材料及其构建的脂质体作为抗肿瘤药物载体的研究

《功能性膜材料及其构建的脂质体作为抗肿瘤药物载体的研究》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、学校代码：10600学号：091050学位类型：科学学位广西中医药大学硕士学位论文功能性膜材料及其构建的脂质体作为抗肿瘤药物载体的研究研究生：丘一仙导师：王志萍教授俸灵林副研究员院系（部所）：药学院专业：药剂学研究方向：药物新制剂、新剂型的研制与开发完成日期：2012年5月15日1目录中文摘要···········································································1英文摘要······································

2、·····································3主要缩略语注释表·····························································6引言············································································8正文··········································································10

3、第一部分功能性膜材料的合成及表征······························101实验材料和仪器·····························································102实验方法·········································································112.1GALA-SA的合成及表征··················································

4、···112.2Folate-Cys的合成及表征······················································132.3Folate-PEG3500-DSPE的合成及表2征·········································152.4MCP多肽的合成及表征······················································163结果与讨论·····································

5、·································173.1GALA-SA的合成与表征····················································173.2Folate-Cys的合成与表征·····················································193.3Folate-PEG3500-DSPE的合成及纯度检测···································203.4MCP的合成与表征·······

6、·····················································214小结··············································································22第二部分Folate-PEG-脂质体递药系统的构建及表征························231材料与仪器···································································

7、···232实验方法·········································································242.1脂质体递药系统的构建·······················································242.2Folate-PEG-脂质体/阿霉素（FA-P-LS/DOX）的构建及表3征··············262.3Folate-PEG-脂质体/FAM（FA-P-LS/FAM）的构建及表征·············

8、····282.4GALA-脂质体（G-LS）的构建及pH敏感性评价···························283结果与讨论······································································293.1制